We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioo Scientific Releases new T3™ Conjugation Kit
Product News

Bioo Scientific Releases new T3™ Conjugation Kit

Bioo Scientific Releases new T3™ Conjugation Kit
Product News

Bioo Scientific Releases new T3™ Conjugation Kit


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bioo Scientific Releases new T3™ Conjugation Kit"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioo Scientific has announced the release of its new T3™ Conjugation Kit, which is designed for scientists to specifically target any cell type for silencing with RNAi. It can be used in vivo or with primary cell lines in vitro.

The T3 Conjugation Kit offers effective in vivo delivery of siRNA and miRNA targeted to almost any cell or tissue. This technology reduces the chance of off target effects since the systemically delivered siRNA vehicle locates and targets specific cells and tissues reducing the amount of siRNA required for silencing.

The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cell lines consisting of mixed cell populations. The patent pending T3 technology functions by conjugating a T3 Carrier to an antibody that can identify a receptor or other extracellular domain specific to the targeted cell or tissue type.

The T3 Carrier-Antibody conjugate  may then be loaded with siRNA and delivered systemically or locally in vivo or in vitro. Targeted cells or tissues then take up the T3 Conjugate and the siRNA is released.
Advertisement